REGENXBIO Highlights Manufacturing and Duchenne Data at ASGCT 2026
Event summary
- REGENXBIO will present at the ASGCT 2026 Annual Meeting in Boston, May 11-15, 2026.
- Oral presentations include updates on NAVXpress® manufacturing platform and RGX-202 Duchenne data.
- Poster sessions highlight capsid engineering advancements for retinal and rare diseases.
- RGX-202 pivotal data to be featured in encore presentation.
The big picture
REGENXBIO's presentations at ASGCT 2026 underscore its leadership in AAV gene therapy manufacturing and clinical development. The focus on Duchenne muscular dystrophy and retinal diseases aligns with growing demand for one-time curative treatments. The company's partnerships with AbbVie and Nippon Shinyaku further validate its pipeline potential.
What we're watching
- Manufacturing Efficiency
- How NAVXpress® advancements will impact production costs and scalability.
- Duchenne Market Position
- Whether RGX-202 data can position REGENXBIO as a leader in Duchenne treatments.
- Capsid Engineering
- The pace at which NVG82 and other engineered capsids advance retinal disease applications.
Related topics